Covaxin has been approved by the Drugs Controller General of India (DCGI) for Phase II/III clinical trials in the age group of 2 to 18 years, Dr. VK Paul, Member-Health, Niti Aayog has said.
“I have been told that trials will begin in the next 10-12 days,” he added.
In a recently released media statement, the Serum Institute of India has stated that it has never exported vaccines at the cost of people in India and remains committed to supporting the vaccination drive in the country.
“A vaccination drive for such a large population can’t be completed within 2-3 months, as several factors & challenges are involved. It’d take 2-3 years for the entire world population to get fully vaccinated,” SII stated.
Holding a health briefing, Lav Aggarwal, Joint Secretary, Ministry of Health, on COVID-19, said on Tuesday, “1.8% of the total population of India has been affected by the disease so far. We have been able to contain the spread of the infection to under 2% of the population. A total of 199 districts in the country are showing a continued decline in cases and positivity since the last three weeks.”
Surjitt Sahani
